Silexion Therapeutics Corp (NASDAQ:SLXN) price on Wednesday, January 15, fall -11.86% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.56.
A look at the stock’s price movement, the close in the last trading session was $1.77, moving within a range at $1.5015 and $1.81. The beta value (5-Year monthly) was -0.111. Turning to its 52-week performance, $122.02 and $1.75 were the 52-week high and 52-week low respectively. Overall, SLXN moved -53.29% over the past month.
Silexion Therapeutics Corp’s market cap currently stands at around $2.50 million, with investors looking forward to this quarter’s earnings report slated for in February.
SLXN’s current price about -29.73% and -36.77% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.38, while 7-day volatility ratio is 16.37% and 18.10% in the 30-day chart. Further, Silexion Therapeutics Corp (SLXN) has a beta value of 0.03, and an average true range (ATR) of 0.39.
If we refocus on Silexion Therapeutics Corp (NASDAQ:SLXN), historical trading data shows that trading volumes averaged 0.84 over the past 10 days and 916.54K over the past 3 months. The company’s latest data on shares outstanding shows there are 1.24 million shares.
The 35.02% of Silexion Therapeutics Corp’s shares are in the hands of company insiders while institutional holders own 8.09% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 35842.0 on 2024-11-15, giving us a short ratio of 0.23. The data shows that as of 2024-11-15 short interest in Silexion Therapeutics Corp (SLXN) stood at 308.0 of shares outstanding, with shares short rising to 9885.0 registered in 2024-10-15. Current price change has pushed the stock -22.39% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SLXN stock continues to rise going into the next quarter.
